Millennium Management LLC Raises Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Millennium Management LLC lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 34.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,948,552 shares of the company's stock after buying an additional 502,853 shares during the period. Millennium Management LLC owned about 1.31% of Xeris Biopharma worth $6,606,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of XERS. JPMorgan Chase & Co. raised its stake in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock worth $3,537,000 after buying an additional 651,481 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $2,014,000. Renaissance Technologies LLC raised its stake in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after buying an additional 500,120 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $1,610,000. Finally, AIGH Capital Management LLC raised its stake in shares of Xeris Biopharma by 17.8% during the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock worth $8,729,000 after buying an additional 389,192 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This represents a 2.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 6.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

XERS has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners upped their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Finally, Piper Sandler restated a "neutral" rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Xeris Biopharma Price Performance

NASDAQ:XERS traded up $0.26 during trading hours on Thursday, reaching $5.04. 1,693,172 shares of the company traded hands, compared to its average volume of 1,967,998. The firm's 50-day moving average is $4.67 and its 200-day moving average is $4.01. The stock has a market cap of $788.18 million, a P/E ratio of -11.20 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.96 and a 1-year high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.